- Home
- /Borrelia burgdorferi Ab.IgM
Borrelia burgdorferi Ab.IgM
Detects early-stage IgM antibodies against Lyme disease bacteria in serum or plasma.
Why This Biomarker Matters
Identifies active or recent Lyme disease affecting the nervous system, enabling prompt antibiotic treatment to prevent serious neurological complications.
Overview
This test detects IgM antibodies against Borrelia burgdorferi in serum or plasma, indicating acute or recent Lyme disease infection. IgM antibodies typically appear within 1-2 weeks of a tick bite and peak around 3-6 weeks. A positive result in the appropriate clinical context (erythema migrans rash, tick exposure, endemic area) supports early Lyme disease diagnosis. Testing follows the CDC-recommended two-tier protocol: initial ELISA screening followed by confirmatory Western blot. IgM results should be interpreted cautiously after 30 days of symptoms, as persistent IgM alone may represent a false positive.
Technical Information (LOINC Codes)
Standardized laboratory codes for this biomarker
40612-4Primary5064-113205-030526-814078-05065-823984-822133-322135-816482-213203-523982-27818-86321-422134-131269-422132-543076-943573-521119-313207-696427-022137-498208-222136-6Available Lab Tests
Order tests that measure this biomarker